Bright Rock Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blackrock
BLK
|
+$10.3M |
| 2 |
Arista Networks
ANET
|
+$4.56M |
| 3 |
SLB Ltd
SLB
|
+$4.1M |
| 4 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$3.4M |
| 5 |
PepsiCo
PEP
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Colgate-Palmolive
CL
|
+$5.82M |
| 2 |
Mastercard
MA
|
+$5.44M |
| 3 |
JPMorgan Chase
JPM
|
+$3.82M |
| 4 |
Starbucks
SBUX
|
+$2.07M |
| 5 |
Veeva Systems
VEEV
|
+$1.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.13% |
| 2 | Financials | 16.85% |
| 3 | Healthcare | 13.67% |
| 4 | Industrials | 8.92% |
| 5 | Consumer Discretionary | 8.83% |
Similar funds
Bright Rock Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Bright Rock Capital Management held 76 positions worth $475M, up 1.2% from $469M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Bright Rock Capital Management deployed $15.3M of net new capital in Q1 2025, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Blackrock: 10,500 shares worth $9.94M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Colgate-Palmolive, an estimated $5.82M trimmed.
- Bright Rock Capital Management's largest Q1 2025 buy was Blackrock: 10,500 shares worth $9.94M.
- Bright Rock Capital Management added most to SLB Ltd in Q1 2025, an estimated $4.1M increase.
- Bright Rock Capital Management's biggest Q1 2025 reduction was Colgate-Palmolive, cutting an estimated $5.82M.
- Bright Rock Capital Management's ten largest holdings make up 34% of its $475M portfolio in Q1 2025.
- Bright Rock Capital Management opened 5 new positions and closed 0 in Q1 2025.
- Bright Rock Capital Management's portfolio value rose 1.2% quarter-over-quarter to $475M.
Based on Bright Rock Capital Management's 13F filing for Q1 2025, filed 16 Apr 2025.